

## Special Issue

# CRISPR in Cancer Biology and Therapy: 2nd Edition

### Message from the Guest Editor

Cancer is a disease of the genome, initiated by the activation of oncogenes and the inactivation of tumor suppressors. It is also a disease of the cell, feeding off changes in metabolism and motility and allowing cells to grow in different environments. Understanding how genomic changes drive the initiation of individual cancers is crucial for developing more effective treatment options and improving outcomes for patients with cancer. CRISPR has been utilized as a tool for programmable genome modifications in almost all cell types. The development of different CRISPR-mediated genome editing tools continues to drive major advances in the life sciences. In cancer research, CRISPR-related tools have greatly advanced our understanding of cancer genetics and tumor heterogeneity, providing new insights into therapeutic vulnerabilities. This Special Issue will focus on the development of CRISPR systems as a tool to study cancers, and the emerging adaptation of these technologies to improve diagnosis and treatment.

### Guest Editor

Dr. Shun-Qing Liang

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota Twin Cities, Phillips-Wangensteen Building RM 1-207, 516 Delaware Street SE, Minneapolis, MN 55455, USA

### Deadline for manuscript submissions

31 July 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/218760](https://mdpi.com/si/218760)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)